In Depth 16 Sep 2018 Meet the Entrepreneurs Doing Biotech from Shipping Containers in London Creative biotech startups are brewing inside a shipping container park that offers affordable research space for biologists, engineers and designers working together. The space, called Open Cell, will be opening… September 16, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2023 Evonetix closes $24M financing Evonetix Ltd, a synthetic biology company bringing semiconductor technology to DNA synthesis, has completed a $24 million financing round, extending its total series B funding to over $54 million. This… February 7, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 A €344M Partnership will Develop Bicycle Drugs for Hemophilia Bicycle Therapeutics has partnered with Bioverativ to develop a new class of drugs for patients with rare blood disorders like hemophilia and sickle cell disease. Bicycle Therapeutics, a money-magnet biotech… September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2017 A London Biotech Aims to Overtake the Dry Eye Syndrome Market TopiVert has released the results of a clinical trial that the company believes yielded “the best proof of concept data in dry eye syndrome.” Based in London, the biotech company… December 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jun 2019 The 10 Biotech Companies in London to Keep an Eye on in 2019 Which biotechs will be stealing the show this year? These are some of the most exciting biotech companies in London right now. London is undoubtedly one of the biggest hubs… June 10, 2019 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Opinion 12 Dec 2022 Artificial intelligence: a new era in rare genetic disease diagnosis Despite the onset of the genomics era, rare disease diagnosis remains a challenge. Nostos Genomics’ co-founder, Rocío Acuña Hidalgo, and chief operating officer, Ansgar Lange, shed light on how artificial… December 12, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2019 First Potential Chlamydia Vaccine Shows Early Promise A vaccine targeting the sexually transmitted infection chlamydia, which would be the first of its kind if approved, has proved safe and able to stimulate the immune system in a… August 16, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 28 Nov 2016 Needle-Free Diabetes Monitoring: Interview with the Co-Founder of GlucoWise The needle-free revolution for diabetes is coming! We interviewed Panos Kosmas, co-founder of MediWise, to get the juicy details of GlucoWise. This revolutionary wireless device could free the more than… November 28, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 New breast cancer treatment receives funding Researchers at Queen’s University Belfast in Northern Ireland have received funding from Breast Cancer Now to search for new treatments inspired by COVID-19 vaccine innovation. The research team will adapt… August 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Labiotech adds conference and event listings In the past few months, Labiotech.eu has boosted its coverage range to go global, added a podcast, expanded to three weekly newsletters, introduced special monthly newsletters, and now we’ve added… September 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Research identifies new treatment target for CNS injury and neurological disease Researchers in Birmingham in the U.K. have identified a potential target for drugs to treat long-term neurological conditions like Alzheimer’s Disease and foster nerve regeneration in central nervous system injuries…. September 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Replay receives $1.5M grant for hypoimmunogenic technology platform Genome writing company Replay has received a $1.56 million grant from the Bill & Melinda Gates Foundation to accelerate the development of uCell, a proprietary hypoimmunogenic technology platform. Replay’s uCell… November 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email